Bradmer Pharmaceuticals Inc. (TSE:GLX – Free Report) – Atb Cap Markets lowered their FY2025 earnings per share (EPS) estimates for shares of Bradmer Pharmaceuticals in a research report issued on Wednesday, April 23rd. Atb Cap Markets analyst M. Toner now anticipates that the company will post earnings per share of ($0.97) for the year, down from their previous forecast of ($0.92).
Several other brokerages have also weighed in on GLX. Cantor Fitzgerald upgraded shares of Bradmer Pharmaceuticals to a “strong-buy” rating in a report on Tuesday, February 25th. BTIG Research raised Bradmer Pharmaceuticals to a “strong-buy” rating in a research report on Monday, April 14th. Finally, Benchmark raised shares of Bradmer Pharmaceuticals to a “strong-buy” rating in a report on Monday, March 31st.
Bradmer Pharmaceuticals Stock Performance
See Also
- Five stocks we like better than Bradmer Pharmaceuticals
- Airline Stocks – Top Airline Stocks to Buy Now
- Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet
- With Risk Tolerance, One Size Does Not Fit All
- Coca-Cola Company Stock Can Bubble to New Highs This Year
- What is the Nasdaq? Complete Overview with History
- 3 Stocks Lifting 2025 Guidance Despite Market Jitters
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
